triazoles has been researched along with Ovarian Neoplasms in 81 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.23) | 18.7374 |
| 1990's | 3 (3.70) | 18.2507 |
| 2000's | 19 (23.46) | 29.6817 |
| 2010's | 48 (59.26) | 24.3611 |
| 2020's | 10 (12.35) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA | 1 |
| Amero, P; Bayraktar, E; Coleman, RL; Dasari, SK; Glassman, D; Handley, KF; Ivan, C; Joseph, R; Kim, M; Landesman, Y; Ma, S; Nguyen, N; Powell, RT; Ram, PT; Rodriguez-Aguayo, C; Sobieski, M; Sood, AK; Stephan, C; Stur, E; Umamaheswaran, S; Wen, Y; Westin, SN | 1 |
| Alotaibi, F; Halaweish, F; Halaweish, H; Iram, S; Kasten, A; Kyeremateng, J; Ostlund, T | 1 |
| Anastasia, A; Baakza, H; Bani, MR; Cadogan, EB; Chiorino, G; Dellavedova, G; Ghilardi, C; Giavazzi, R; James, N; Ramos-Montoya, A; Russo, M; Wilson, J | 1 |
| Achar, RR; Alfaifi, MY; Barache, UB; Deodware, SA; Dhale, PC; Elbehairi, SEI; Flores-Holguín, N; Frau, J; Gaikwad, KD; Gaikwad, SH; Glossman-Mitnik, D; Kollur, SP; Shati, AA; Shivamallu, C; Silina, E; Stupin, V; Ubale, PA | 1 |
| Burgos, M; Esparís-Ogando, A; Galán-Moya, EM; Gómez-Juárez, M; Montero, JC; Nieto-Jimenez, C; Noblejas-López, MDM; Ocaña, A; Pandiella, A | 1 |
| Correia, C; Dowdy, SC; Ekstrom, TL; Heinzen, EP; Hitosugi, T; Hou, X; Huntoon, CJ; Kanakkanthara, A; Karnitz, LM; Kaufmann, SH; Kurmi, K; Li, H; O'Brien, D; Oberg, AL; Purfeerst, ER; Wahner Hendrickson, AE; Weroha, SJ | 1 |
| Arapinis, C; Bagratuni, T; Bamias, A; Christodoulou, MI; Dimopoulos, MA; Gavalas, NG; Haidopoulos, D; Kastritis, E; Liontos, M; Mavrianou, N; Rodolakis, A; Scorilas, A; Thomakos, N; Tzannis, K | 1 |
| Chen, XS; Cheng, Y; Li, LY; Tian, M; Wang, XL; Wu, HZ; Xiao, SS; Zeng, D; Zhang, Y | 1 |
| Addi, L; Alfano, L; Baldassarre, G; Bruzzese, F; Budillon, A; Capone, F; Costa, A; Di Gennaro, E; Iannelli, F; Lombardi, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sonego, M | 1 |
| Bamel, K; Eskander, RN; Ikeda, S; Kato, S; Kurzrock, R; McFall, T; Parker, B; Plaxe, S; Stites, E; Takahashi, K | 1 |
| Ekstrom, TL; Huehls, AM; Kanakkanthara, A; Karnitz, LM; Pathoulas, NM | 1 |
| Block, MS; Colon-Otero, G; Copland, JA; Dinh, TA; Foster, NR; Haluska, P; Hou, X; Jatoi, A; Robertson, MW; Wahner-Hendrickson, AE; Weroha, SJ | 1 |
| Beale, PJ; Bonaventura, A; DeFazio, A; Friedlander, ML; Goh, JCH; Grant, PT; Hadley, AM; Mapagu, C; Martyn, J; McNally, OM; Mileshkin, LR; OʼConnell, RL; Scurry, J; Sjoquist, KM | 1 |
| Beltran, H; Demichelis, F; Rickman, DS; Rubin, MA | 1 |
| Banerjee, S; Della Pepa, C; George, A; Gore, M; Kaye, S; McLachlan, J; Migali, C; Tunariu, N | 1 |
| Dang, CV; Fan, L; Fan, Y; Hu, X; Hu, Z; Huang, Q; Li, C; Montone, K; Pi, J; Shan, W; Tang, Z; Tanyi, JL; Wang, Y; Yang, L; Yuan, J; Zhang, L; Zhang, Y | 1 |
| Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G | 1 |
| Assi, T; El Rassy, E; Kattan, J; Kourie, HR; Moussa, T | 1 |
| Argueta, C; Carenini, N; Ciusani, E; Corno, C; De Cesare, M; Gatti, L; Landesman, Y; Minoli, L; Perego, P; Scanziani, E; Stamatakos, S; Stucchi, S; Zaffaroni, N | 1 |
| Friedlander, M; Heinzelmann-Schwarz, V; Jacob, F; Knipprath Mészaros, A; Russell, K; Schoetzau, A; Singer, G; Stadlmann, S; Vetter, M | 1 |
| Bitler, BG; Fatkhutdinov, N; Karakashev, S; Khabele, D; Kossenkov, AV; Simpkins, F; Speicher, D; Wilson, AJ; Yokoyama, Y; Zhang, R; Zhao, B; Zhu, H | 1 |
| Alomary, M; Antony, J; Cunnea, P; Fotopoulou, C; Gabra, H; Huang, RY; Jung, Y; Karali, E; Kelly, Z; Mills, GB; Nixon, K; Paterson, A; Recchi, C; Roy-Nawathe, S; Tan, TZ; Thiery, JP; Zanini, E | 1 |
| Cong, Q; Gao, T; Jiang, W; Sun, M; Wang, Y; Xu, C; Yao, L; Yu, Y | 1 |
| Beck-Noia, H; Fuh, KC; Greenwade, MM; Guo, L; Hagemann, AR; Hagemann, IS; Massad, K; McCourt, CK; Mutch, DG; Opara, G; Palisoul, ML; Powell, MA; Quinn, JM; Thaker, PH; Zhao, P | 1 |
| Altwerger, G; Ardighieri, L; Azodi, M; Bellone, S; Bianchi, A; Bignotti, E; Bonazzoli, E; Buza, N; Choi, J; Dong, W; Han, C; Huang, GS; Hui, P; Li, C; Lifton, RP; Litkouhi, B; Lopez, S; Manara, P; Manzano, A; Menderes, G; Odicino, F; Pecorelli, S; Pettinella, F; Ratner, E; Ravaggi, A; Riccio, F; Romani, C; Santin, AD; Schlessinger, J; Schwartz, PE; Silasi, DA; Todeschini, P; Wong, S; Yadav, G; Yang-Hartwich, Y; Zammataro, L; Zanotti, L; Zeybek, B; Zizioli, V | 1 |
| Jia, Y; Jian, W; Jin, H; Lin, R; Si, L; Yang, S; Yu, Q | 1 |
| Astsaturov, I; Connolly, DC; Golemis, EA; Litwin, S; Liu, H; Maglaty, MA; Martin, LP; O'Brien, SW; Proia, DA; Serebriiskii, IG; Xiao, F | 1 |
| Chen, YF; Dong, Z; Lai, D; Peng, L; Tang, J; Wang, S; Xia, Y | 1 |
| Antoun, J; Kattan, J; Kourie, HR; Sleilaty, F | 1 |
| Hirakawa, H; Mizunuma, H; Yokoyama, Y; Yoshida, H | 1 |
| Alexandre, J; Bigenwald, C; Deval, B; Nogales, FF; Rousset, P | 1 |
| Bagchi, IC; Bagchi, MK; Haschek, WM; Kannan, A; Laws, MJ; Pawar, S | 1 |
| Cai, Q; Hong, S; Jiang, W; Xu, C; Yu, Y; Zhang, M; Zhang, X | 2 |
| Esfahani, K; Ferrario, C; Le, P; Panasci, L | 1 |
| Guseĭnov, KD; Livshits, MA; Vasil'ev, BV | 1 |
| Babacan, A; Duru, NK; Ercan, CM; Ergun, A; Keskin, U; Korkmaz, C; Yilmaz, A | 1 |
| Garde-Granger, P; Lane, D; Laplante, C; Matte, I; Piché, A; Rancourt, C | 1 |
| Bae-Jump, VL; Chan, LL; Gehrig, PA; Jackson, AL; Kilgore, JE; Qiu, H; Zhong, Y; Zhou, C | 1 |
| Chen, H; Ding, HF; Dong, Z; Fang, D; Huang, S; Jing, Q; Lu, Y; Su, SB; Yang, L | 1 |
| Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS | 1 |
| Buckel, E; Rodríguez, T; Wash, A; Yazigi, R | 1 |
| Cai, MC; Di, W; Gao, WQ; Gu, Z; Ji, ZL; Jing, Y; Ma, P; Peng, H; Yan, Y; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G | 1 |
| Aryasomayajula, B; Degterev, A; Deshpande, PP; Hartner, WC; Kulkarni, A; Nagelli, SG; Pattni, BS; Thakur, G; Torchilin, VP | 1 |
| Antony, J; Choolani, M; Gabra, H; Huang, RY; Kelly, Z; Low, J; Recchi, C; Tan, TZ; Thiery, JP | 1 |
| Bitler, BG; Bradner, JE; Conejo-Garcia, JR; Gardini, A; Kossenkov, AV; Lee, JH; Liu, Q; Ordog, T; Palozola, KC; Showe, LC; Sood, AK; Speicher, D; Wickramasinghe, JM; Wu, SY; Yin, X; Yokoyama, Y; Zaret, KS; Zhang, R; Zhang, Z; Zhu, H | 1 |
| Bastians, H; Concin, N; Dobbelstein, M; Edmunds, S; Erytch, N; Kramer, D; Moll, UM; Roßmann, L; Schulz-Heddergott, R; Stark, N | 1 |
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Al Mufti, R; Behranwala, K; Hadjiminas, DJ; Lanitis, S; Sivakumar, S; Zacharakis, E | 1 |
| Beiner, M; Ben-Baruch, G; Davidzon, T; Fridman, E; Korach, J; Perri, T | 1 |
| Blinman, P; Tattersall, MH | 1 |
| Babayev, SN; Barad, D; Kim, JY; Oktay, K | 1 |
| Jang, ER; Kim, W; Kim, YJ; Lee, CS; Myung, SC | 1 |
| Curiel, TJ; Daniel, BJ; Fan, J; Jin, D; Liu, A; Shin, T; Thompson, LF; Wang, L; Zhang, B | 1 |
| Ahmad, I; Chhikara, BS; Kumar, A; Mandal, D; Parang, K; Tiwari, R | 1 |
| Bai, L; Lu, J; McEachern, D; Sun, H; Wang, S; Yang, CY | 1 |
| Beale, TM; Bond, PJ; Brenton, JD; Charnock-Jones, DS; Ley, SV; Myers, RM | 1 |
| Kaczor, AA; Karczmarzyk, Z; Matosiuk, D; Pitucha, M; Rzymowska, J; Wysocki, W | 1 |
| Abdul Munem, A; Al-Bahrani, B; Kamona, A; Mehdi, I; Nadas, AM | 1 |
| Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K | 1 |
| Bowman, A; Gabra, H; Langdon, SP; Lessells, A; Smyth, JF; Stewart, M; Young, A | 1 |
| Figg, WD; Hussain, MM; Kohn, EC; Kotz, H; Minasian, L; Oliver, VK; Premkumar, A; Raggio, M; Reed, E; Sarosy, G; Steinberg, SM; Zhai, S | 1 |
| Campos, S; del Carmen, MG; Duska, LR; Fuller, AF; Goodman, A; Horick, NK; Matulonis, U; Penson, R; Roche, M; Seiden, MV | 1 |
| Dimopoulos, MA; Efstathiou, E; Grimani, I; Hamilos, G; Markaki, S; Papadimitriou, CA; Siapkaras, J; Vlachos, G; Zorzou, M | 1 |
| Miller, DS; Rao, GG | 1 |
| Cunat, S; Daurès, JP; Katsaros, D; Maudelonde, T; Miller, WR; Pujol, P; Rabenoelina, F; Sasano, H | 1 |
| Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R | 1 |
| Freeman, SA; Modesitt, SC | 1 |
| Cameron, DA; Langdon, SP; MacLeod, K; Smyth, JF; Walker, G; Williams, AR | 2 |
| Gabra, H; Gourley, C; Langdon, SP; MacKean, MJ; Mano, M; McCurdy, J; McMahon, T; Nafussi, AA; Reed, N; Rye, R; Rye, T; Smyth, JF; Stevenson, A; Stewart, M; Vasey, P; Walker, G; Williams, AR | 1 |
| Raj Pandey, K | 1 |
| Coleman, RL; Deavers, M; Gershenson, DM; Kavanagh, JJ; Levenback, C; Milam, MR; Ramirez, PT; Schmeler, KM; Slomovitz, BM; Smith, JA | 1 |
| Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y | 1 |
| Friedrich, MJ | 1 |
| Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
| Kohn, EC; Liotta, LA; Sandeen, MA | 1 |
| Barash, L; Beattie, T; Bochis, RJ; Brown, JE; Chabala, JC; Graham, DW; Harris, E; Peterson, LH; Tischler, M; Waksmunski, FS | 1 |
| Carnino, F; Dodion, P; George, M; Rotmensz, N; Scotto, V; ten Bokkel Huinink, WW; Vermorken, JB | 1 |
3 review(s) available for triazoles and Ovarian Neoplasms
| Article | Year |
|---|---|
Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fertility Preservation; Humans; Letrozole; Lymphoma, Non-Hodgkin; Nitriles; Oocyte Retrieval; Ovarian Neoplasms; Ovulation Induction; Triazoles | 2014 |
Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.
Topics: Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Tomography, X-Ray Computed; Triazoles | 2012 |
Clinical applications of hormonal therapy in ovarian cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leuprolide; Medroxyprogesterone; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
12 trial(s) available for triazoles and Ovarian Neoplasms
| Article | Year |
|---|---|
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Hydrazines; Lung Neoplasms; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Triazoles; Vomiting | 2022 |
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Disease-Free Survival; Everolimus; Female; Humans; Letrozole; Mice; Mice, SCID; Middle Aged; Neoplasm Grading; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nitriles; Organoplatinum Compounds; Ovarian Neoplasms; Prospective Studies; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Tissue Array Analysis; Triazoles | 2017 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; CA-125 Antigen; Disease Progression; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Immunoenzyme Techniques; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2002 |
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Calcium Channel Blockers; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles | 2003 |
Phase II trial of anastrozole in women with asymptomatic müllerian cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2003 |
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; CA-125 Antigen; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2004 |
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Triazoles | 2007 |
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Letrozole; Nitriles; Ovarian Neoplasms; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2007 |
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Taxoids; Treatment Outcome; Triazoles | 2008 |
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
66 other study(ies) available for triazoles and Ovarian Neoplasms
| Article | Year |
|---|---|
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Female; High-Throughput Screening Assays; Humans; Hydrazines; Mice; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Triazoles | 2021 |
Triazole-estradiol analogs: A potential cancer therapeutic targeting ovarian and colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Estradiol; Female; Humans; Molecular Structure; Ovarian Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Triazoles | 2022 |
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Topics: Animals; Cell Line, Tumor; DNA; Doxorubicin; Female; Heterografts; Humans; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Polyethylene Glycols; Protein Kinase Inhibitors; Purines; Pyrans; Triazoles | 2022 |
In Vitro Anticancer Screening, Molecular Docking and Antimicrobial Studies of Triazole-Based Nickel(II) Metal Complexes.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Apoptosis; Benzaldehydes; Cell Line, Tumor; Coordination Complexes; Female; Humans; Ligands; Microbial Sensitivity Tests; Molecular Docking Simulation; Nickel; Ovarian Neoplasms; Schiff Bases; Spectroscopy, Fourier Transform Infrared; Triazoles | 2022 |
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Proteolysis; Thalidomide; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms | 2019 |
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclin-Dependent Kinases; DNA Methylation; Energy Metabolism; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazones; Hydroxybenzoates; Mice; Mitochondria; Mutation; Nicotinamide N-Methyltransferase; Ovarian Neoplasms; Ovary; Oxidative Phosphorylation; Promoter Regions, Genetic; Tigecycline; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinases; Ovarian Neoplasms; Proto-Oncogene Proteins c-myc; Signal Transduction; STAT Transcription Factors; Transcription Factors; Triazoles | 2020 |
Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxyglucose; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glycolysis; HEK293 Cells; Humans; Mice, Nude; Ovarian Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2021 |
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays | 2021 |
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Topics: Aromatase Inhibitors; Female; Humans; Nitriles; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); Receptors, Estrogen; Tamoxifen; Triazoles | 2021 |
VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cisplatin; Clinical Trials, Phase I as Topic; DNA Breaks, Double-Stranded; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Histone Demethylases; Homologous Recombination; Humans; Hydrazones; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Triazoles; Tumor Cells, Cultured | 2021 |
Biology and evolution of poorly differentiated neuroendocrine tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azepines; Benzodiazepines; Carcinogenesis; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cell Differentiation; Cell Lineage; Cell Plasticity; Colonic Neoplasms; Disease Progression; Epigenesis, Genetic; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Neuroendocrine Tumors; Ovarian Neoplasms; Prostatic Neoplasms; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyrimidines; Retinoblastoma Binding Proteins; Triazoles; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2017 |
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Female; Humans; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Recurrence; Retreatment; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Young Adult | 2017 |
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Topics: Acetanilides; Animals; Antineoplastic Agents; Azepines; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Homologous Recombination; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Triazoles | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2017 |
Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles | 2017 |
FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Exportin 1 Protein; Female; Forkhead Box Protein O1; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Ovarian Neoplasms; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Datasets as Topic; Disease-Free Survival; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Letrozole; Maintenance Chemotherapy; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles; Young Adult | 2018 |
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Topics: Animals; Azepines; BRCA1 Protein; BRCA2 Protein; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; Drug Synergism; Epithelial Cells; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Proteins; Triazoles | 2017 |
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Survival; Chickens; Cholesterol; Enzyme Activation; Epithelial Cells; Fallopian Tubes; Female; Gene Silencing; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Membrane Microdomains; Neoplasm Invasiveness; Ovarian Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Treatment Outcome; Triazoles; Tumor Suppressor Proteins | 2018 |
Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.
Topics: Animals; Azepines; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Disease Progression; Female; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Platelet Activating Factor; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Triazoles; Tumor Microenvironment | 2018 |
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Topics: Animals; Antineoplastic Agents; Azepines; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proteins; Proto-Oncogene Proteins c-myc; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2019 |
Thiophenol-formaldehyde triazole causes apoptosis induction in ovary cancer cells and prevents tumor growth formation in mice model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Formaldehyde; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Ovarian Neoplasms; Phenols; Structure-Activity Relationship; Sulfhydryl Compounds; Triazoles; Tumor Cells, Cultured | 2019 |
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Flow Cytometry; Gene Regulatory Networks; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; RNA, Small Interfering; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Nucleoside analog inhibits microRNA-214 through targeting heat-shock factor 1 in human epithelial ovarian cancer.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Female; Heat Shock Transcription Factors; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Chaperones; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Nucleosides; Ovarian Neoplasms; RNA Interference; Transcription Factors; Triazoles | 2013 |
Letrozole efficacy in the treatment of granulosa cell tumor of the ovary: a case report.
Topics: Antineoplastic Agents; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Radiography; Treatment Outcome; Triazoles | 2013 |
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase; Aromatase Inhibitors; Ascites; Cell Line, Tumor; Estrogen Receptor alpha; Female; Forkhead Transcription Factors; Humans; Letrozole; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Nitriles; Ovarian Neoplasms; Ovariectomy; Peritoneal Neoplasms; Repressor Proteins; Signal Transduction; Time Factors; Triazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor.
Topics: Anastrozole; Aromatase Inhibitors; Ependymoma; Female; Humans; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles | 2014 |
Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice.
Topics: Animals; Carcinogenesis; Carcinoma, Ovarian Epithelial; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; Hypothalamus; Letrozole; Mice; Neoplasms, Glandular and Epithelial; Nitriles; Ovarian Neoplasms; Ovary; Pituitary Gland; Signal Transduction; Triazoles | 2014 |
Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Ovarian Neoplasms; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Quinazolines; Receptors, G-Protein-Coupled; Signal Transduction; Triazoles; Tyrphostins; Xenograft Model Antitumor Assays | 2014 |
The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Nucleus; Cisplatin; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MAP Kinase Signaling System; Mice, Nude; Ovarian Neoplasms; Platelet Membrane Glycoproteins; Protein Transport; Receptors, G-Protein-Coupled; Transcription Factor RelA; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Splenectomy; Splenic Neoplasms; Triazoles | 2014 |
[The use of letrozole in ovarian cancer].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Treatment Outcome; Triazoles | 2014 |
Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Topics: Ascites; Cell Movement; Cells, Cultured; Cytokines; Enzyme Activation; Epithelial Cells; ErbB Receptors; Female; Hepatocyte Growth Factor; Humans; Immunoblotting; Inflammation Mediators; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; Peritoneal Cavity; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyrazines; Signal Transduction; Triazoles | 2015 |
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Membrane Potential, Mitochondrial; Mice; Necrosis; Neoplasm Metastasis; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proto-Oncogene Proteins c-myc; Reactive Oxygen Species; RNA Interference; Transcriptome; Triazoles | 2015 |
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Topics: Animals; Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Oncogene Proteins; Ovarian Neoplasms; Oxazoles; RNA, Small Interfering; Thiazoles; Triazoles | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles | 2015 |
Ovarian granulosa cell tumour and letrozole: A case report.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Granulosa Cell Tumor; Humans; Letrozole; Liver Neoplasms; Middle Aged; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Retreatment; Triazoles | 2016 |
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma; Cell Line, Tumor; Down-Regulation; Female; Forkhead Box Protein M1; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Pteridines; Transcription Factors; Triazoles | 2016 |
Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.
Topics: Apoptosis; Cell Line, Tumor; Chlorophenols; Drug Delivery Systems; Female; Humans; Liposomes; Micelles; Ovarian Neoplasms; Prodrugs; Transferrin; Triazoles; Tumor Cells, Cultured | 2016 |
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Chick Embryo; Female; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2016 |
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Azepines; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Retinal Dehydrogenase; Transcription Factors; Triazoles | 2016 |
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; DNA Damage; DNA Fragmentation; DNA Helicases; Drug Therapy, Combination; Fanconi Anemia Complementation Group A Protein; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Mitosis; Ovarian Neoplasms; Transplantation, Heterologous; Triazoles; Tripartite Motif-Containing Protein 28; Tumor Suppressor Protein p53 | 2017 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
A case of Meigs syndrome mimicking metastatic breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; CA-125 Antigen; Carcinoma, Ductal, Breast; Diagnosis, Differential; Female; Fibroma; Gynecologic Surgical Procedures; Humans; Letrozole; Mastectomy; Meigs Syndrome; Middle Aged; Nitriles; Ovarian Neoplasms; Pleural Effusion; Triazoles | 2009 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Ovariectomy; Prognosis; Treatment Outcome; Triazoles | 2009 |
A case of uterine tumour resembling ovarian sex cord tumour responding to second-line, single agent anastrazole.
Topics: Anastrozole; Diagnosis, Differential; Female; Humans; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles; Uterine Neoplasms | 2009 |
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Topics: Adult; Breast Neoplasms; Female; Genes, BRCA1; Humans; Infertility; Letrozole; Mutation; Nitriles; Ovarian Neoplasms; Ovary; Ovulation Induction; Risk; Triazoles | 2010 |
Casein kinase 2 inhibition differentially modulates apoptotic effect of trichostatin A against epithelial ovarian carcinoma cell lines.
Topics: Animals; Apigenin; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Nucleus; DNA Fragmentation; Epithelium; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Ovarian Neoplasms; Signal Transduction; Triazoles | 2010 |
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Apoptosis; Female; Flow Cytometry; Immunotherapy, Adoptive; Mice; Mice, Inbred C57BL; Mice, Knockout; Ovarian Neoplasms; Pyrimidines; Receptor, Adenosine A2A; RNA, Small Interfering; T-Lymphocytes; Triazoles | 2010 |
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Ovarian Neoplasms; Pyrans; Pyrimidines; src-Family Kinases; Triazoles | 2011 |
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
Topics: Animals; Apoptosis Regulatory Proteins; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, SCID; Mitochondrial Proteins; Ovarian Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction; Triazoles; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2012 |
Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Female; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Ovarian Neoplasms; Stilbenes; Structure-Activity Relationship; Triazoles; Tubulin | 2012 |
Structural and molecular docking studies of 4-benzyl-3-[(1-methylpyrrol- 2-yl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one with anticancer activity.
Topics: Antineoplastic Agents; Binding Sites; Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Female; Humans; Isomerism; Molecular Docking Simulation; Molecular Structure; Ovarian Neoplasms; Pyrroles; Triazoles | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blepharitis; Breast Neoplasms; Conjunctival Diseases; Dry Eye Syndromes; Female; Humans; Keratitis; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Retrospective Studies; Triazoles; Vision Disorders | 2013 |
Aromatase expression in ovarian epithelial cancers.
Topics: Androstadienes; Aromatase; Aromatase Inhibitors; Cell Proliferation; Cysts; Epithelial Cells; Estrogen Receptor alpha; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lasers; Letrozole; Microdissection; Middle Aged; Neoplasms, Glandular and Epithelial; Nitriles; Ovarian Neoplasms; Ovary; Polymerase Chain Reaction; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 2005 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Floxuridine; Humans; Hysterotomy; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Nitriles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Triazoles | 2005 |
Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Triazoles | 2006 |
Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
Topics: Antineoplastic Agents; CA-125 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Humans; Immunohistochemistry; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor Binding Proteins; Letrozole; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2007 |
Letrozole effective in ovarian cancer.
Topics: Antineoplastic Agents; Female; Humans; Letrozole; Nitriles; Ovarian Neoplasms; Triazoles | 2007 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosomes, Human; Colonic Neoplasms; Colorimetry; DNA Mismatch Repair; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Male; Neoplasm Invasiveness; Neoplasms; Nifedipine; Ovarian Neoplasms; Prostatic Neoplasms; Transfection; Triazoles; Urinary Bladder Neoplasms | 2008 |
Ovarian cancer investigators aim at cell signaling pathways.
Topics: Animals; Antineoplastic Agents; Calcium Channel Blockers; Cell Division; Chromones; Enzyme Inhibitors; Female; Humans; Morpholines; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Triazoles | 1999 |
In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates.
Topics: Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Arachidonic Acids; Calcium; Cell Division; Cell Line; Cell Transformation, Neoplastic; Colonic Neoplasms; Female; Genes, ras; Humans; Inositol Phosphates; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Rats; Signal Transduction; Transfection; Transplantation, Heterologous; Triazoles | 1992 |
Benzylated 1,2,3-triazoles as anticoccidiostats.
Topics: Alkylation; Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Chickens; Coccidiostats; Eimeria; Female; Ovarian Neoplasms; Triazoles | 1991 |
Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms; Triazoles | 1987 |